. Glucocorticoids abate p70 S6k and eIF4E function in L6 skeletal myoblasts. Am J Physiol Endocrinol Metab 279: E74-E82, 2000.-The catabolic properties of glucocorticoid hormones are largely attributable to dual regulation of protein degradation and synthesis. With regard to the latter, glucocorticoids modulate the translational machinery, namely that component functional in translation initiation. This investigation revealed that in L6 myoblasts, dexamethasone, a synthetic glucocorticoid, deactivated the ribosomal protein S6 kinase (p70 S6k ) within 4 h, as evidenced by diminished phosphorylation of its physiological substrate, the 40S ribosomal protein S6. This deactivation correlated with dephosphorylation of p70
eIF4E binding protein; eIF4G; dexamethasone; translation initiation THE PATHOPHYSIOLOGICAL SEQUELAE that derive from hypercortisolism, as observed in Cushing's syndrome or chronic glucocorticoid therapy, are often characterized by a marked loss of lean body mass caused by enhanced proteolysis (10, 27, 34) and/or diminished protein synthesis (29, 30) . Moreover, glucocorticoids are inherently diabetogenic, in that hormonal excess renders peripheral tissues insulin resistant and thus refractory to the metabolic and anabolic processes governed by insulin despite associated hyperinsulinemia. At the cellular level, the mechanisms dictating the catabolic and antianabolic character of glucocorticoids are only now emerging.
Manifestation of the antianabolic effects of glucocorticoids is heralded by an initial series of biochemical events that predispose the cell to nitrogen loss. This acute phase occurs within 4 h and is distinguished in part by attenuation of the cell's protein synthetic apparatus. In particular, the eIF4 class of eukaryotic initiation factors, which coordinately regulate expression of the overwhelming majority of cellular mRNAs, i.e., 7-methylguanosylated mRNAs, is potently affected. Administration of dexamethasone induces dephosphorylation of eIF4E binding protein 1 (4E-BP1), which strengthens its affinity for eIF4E, competitively inhibits eIF4G-eIF4E coupling, and ultimately prevents assembly of the functional eIF4F holocomplex (33) . Not surprisingly, the 70 kDa ribosomal protein S6 kinase (p70 S6k ), which lies downstream of phosphatidylinositol-3 kinase (PI-3 kinase) and appears to be subject to direct or indirect regulation by the mammalian target of rapamycin (mTOR) is simultaneously dephosphorylated in skeletal muscle challenged with dexamethasone. This serine/threonine protein kinase has been implicated in cell cycle progression across the G 1 checkpoint (4, 9, 21) and in the translational selection of transcripts exhibiting a unique 5Ј terminal oligopyrimidine (TOP) signature (16) .
Because glucocorticoids negatively modulate protein synthesis, in part via downregulation of key translation factors, an attempt was undertaken to characterize mechanistically those events that underlie and contribute to this process. Furthermore, the influence of acute glucocorticoid action on signal transduction pathways previously implicated in regulation of p70 S6k and 4E-BP1 was assessed.
EXPERIMENTAL PROCEDURES
Materials. Enhanced chemiluminescence (ECL) detection kits and donkey anti-rabbit and sheep anti-mouse horseradish peroxidase-conjugated IgG were purchased from Amersham Life Sciences. Polyvinylidene difluoride (PVDF) membranes were purchased from Bio-Rad. [ 35 S]Easytag express protein-labeling mix was acquired from NEN Research Prod-ucts. S6k , anti-phospho-Ser 411 -p70 S6k , anti-phosphoThr 389 -p70 S6k , and anti-4E-BP1 antibodies were purchased from Santa Cruz Biotechnology. Anti-PKB (protein kinase B), anti-p38 MAPK (mitogen-activated protein kinase), antiphospho-p38 MAPK , anti-Erk, (extracellular signal-regulated kinase), and anti-phospho-Erk antibodies were purchased from New England Biolabs. Anti-mTOR antibody was a generous gift from Dr. Christopher Lynch (The Pennsylvania State University College of Medicine). Anti-phospho-S6 antibody was a gift from Dr. Morris Birnbaum (The University of Pennsylvania). Dexamethasone sodium phosphate, mifepristone, geldanamycin, actinomycin D, cycloheximide, emetine, puromycin, and rapamycin were purchased from Sigma. Okadaic acid was acquired from GIBCO. Calyculin A was purchased from Calbiochem.
Cell Culture. L6 myoblasts (American Type Culture Collection) were seeded in 60-or 100-mm culture dishes in DMEM supplemented with 10% fetal calf serum (HyClone Labs), 100 U/ml benzylpenicillin, and 100 g/ml streptomycin sulfate. Cells were grown to 70-80% confluence and then induced to quiescence by replacement of the medium with DMEM devoid of serum and antibiotics for 24 h. In some cases, the medium was supplemented with pharmacological agents, as described in the legend of each figure. Subsequently, cells were scraped and lysed in buffer A [20 mM HEPES, pH 7.4, 100 mM KCl, 2.5% Triton X-100, 0.25% deoxycholate, 50 mM NaF, 0.2 mM EDTA, 2 mM EGTA, 1 mM dithiothreitol, 50 mM ␤-glycerophosphate, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 0.2 mM benzamidine, 0.8 M leupeptin and 0. (19) .
Analysis of Western blots. Protein immunoblots were developed via ECL and quantitated by scanning densitometry, as described previously (18, 20) .
Phosphorylation of p70
S6k . An aliquot of L6 cell homogenate was added to an equivalent volume of 2ϫ SDS sample buffer, heated at 95°C for 5 min and then separated into multiple electrophoretic forms by SDS-PAGE. The proteins were then transferred to PVDF membranes, which were subsequently incubated with anti-p70
S6k antibody or antiphosphopeptide antibodies directed against Thr 389 or Ser 411 . It is generally accepted that the electrophoretic mobility of p70
S6k is inversely correlated with its degree of phosphorylation (35) . Because the most highly phosphorylated form, and thus the species exhibiting the slowest migration, is also the most active form of the protein (36) , mobility is typically a reasonable index of p70 S6k activation. However, this form of highly retarded mobility is undetectable under conditions of glucocorticoid exposure. Therefore, the electrophoretic species migrating slower than the lowermost signal, designated herein as p70
S6k -␣, were densitometrically quantitated and expressed as the percentage of total p70
S6k in hyperphosphorylated (relative to p70
S6k -␣) forms; thus the data are indicative of p70
S6k phosphorylation/activation. Quantitation of phosphorylated and unphosphorylated 4E-BP1. Quantitation of the phosphorylation state of 4E-BP1 was carried out exactly as described elsewhere (18) . Briefly, cell lysates were subjected to SDS-PAGE and then immunoblotted with anti-4E-BP1 antibody. Analogous to p70 S6k , the rate of migration of 4E-BP1 is inversely related to increasing phosphorylation of the protein. Three electrophoretic species, referred to as ␣, ␤, and ␥, readily resolve with SDS-PAGE; the most hyperphosphorylated form is denoted ␥, the hypophosphorylated form being denoted ␣.
Quantitation of eIF4E, 4E-BP1 ⅐ eIF4E, and eIF4G ⅐ eIF4E complexes. Quantitation of the respective factors and complexes was carried out exactly as outlined previously (18) . eIF4E, 4E-BP1 ⅐ eIF4E, and eIF4G ⅐ eIF4E complexes were immunoprecipitated from whole cell lysates by use of a mouse monoclonal anti-eIF4E antibody. The immune complexes were isolated by incubation with a goat anti-mouse BioMag IgG bead slurry (PerSeptive Diagnostics). In preparation for incubation with antigen-antibody complexes, the beads were blocked in 0.1% nonfat dry milk in buffer B [50 mM tris(hydroxymethyl)aminomethane (Tris)-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.1% ␤-mercaptoethanol, 0.5% Triton X-100, 50 mM NaF, 50 mM ␤-glycerophosphate, 0.1 mM PMSF, 1 mM benzamidine, and 0.5 mM sodium orthovanadate] for 1 h at 4°C. The beads were captured by means of a magnetic stand, washed twice with buffer B, and washed once with buffer B containing 500 instead of 150 mM NaCl. After incubation of the immune conjugates with magnetic beads, the resultant complexes were eluted in SDS sample buffer and then boiled for 5 min. The beads were pelleted by centrifugation, and the supernatants were collected and subjected to SDS-PAGE. After proteins were separated electrophoretically, they were transferred to PVDF membranes. The membranes were incubated with a mouse monoclonal anti-eIF4E antibody, an anti-4E-BP1 antibody, or a rabbit polyclonal anti-eIF4G antibody overnight at 4°C. Finally, the blots were developed with an ECL Western blotting kit.
Quantitation of phosphorylated and unphosphorylated eIF4E. Quantitation of the percentage of eIF4E in the phosphorylated and unphosphorylated forms was performed by means of slab gel isoelectric focusing with subsequent protein immunoblot analysis, exactly as previously described (37) .
RESULTS
The function of glucocorticoids in catabolic and antianabolic capacities has long been appreciated. To begin to address the underlying molecular phenomena associated with glucocorticoid-regulated protein metabolism, events involved in the assembly of eIF4F, the cellular machinery that facilitates recruitment of mRNA to the ribosome, was assessed. This mRNA binding complex is composed of several polypeptides, including eIF4E, eIF4G, eIF4A, and eIF4B; eIF4G, the largest subunit of the complex, serves as a docking platform for other components of the holoprotein and additional initiation factors, such as eIF3. The association of eIF4E, which recognizes the 5Ј cap of eukaryotic mRNA, with eIF4G is required for loading ribosomes onto the message. Therefore, the formation of the active eIF4F complex represents an important control point for the regulation of translation initiation.
The classical mechanism of glucocorticoid action involves migration of the transformed glucocorticoid receptor into the nucleus, where it physically recognizes specific DNA response elements and thereby transactivates or transrepresses target genes. However, interference of various transcriptional pathways by the liganded glucocorticoid receptor can occur independently of the DNA binding properties of the receptor. Such genomic regulation cumulatively serves to tailor cellular phenotype to environmental demands and is typically preceded by a temporal lag because of the time requirement of mRNA and protein synthesis and/or degradation. Indeed, 2 h of incubation with dexamethasone was required for significant redistribution of total 4E-BP1 into hypophosphorylated species; this occurred concomitantly with disappearance of the ␥-or hyperphosphorylated form of the protein (Fig.  1A) . Furthermore, because 4E-BP1-␥ is the only form of the inhibitor incapable of sequestering eIF4E, the loss of the ␥-form implies that a larger proportion of total eIF4E should be bound by 4E-BP1, thereby limiting its availability. Not surprisingly, co-immunoprecipitation of 4E-BP1 with eIF4E revealed that eIF4E was increasingly coupled to 4E-BP1 in direct relation to the period of incubation with dexamethasone (Fig.  1B) .
The PI-3 kinase signal transduction module that regulates, through phosphorylation, the efficacy of 4E-BP1 mutually affects the phosphorylation and thus the activation state of p70 S6k . Predictably, in cells administered dexamethasone, p70
S6k was markedly dephosphorylated; however, the glucocorticoid required Ն2 h to manifest significant effect. In cells deprived of serum for 24 h, p70
S6k resolves into multiple readily detectable electrophoretic forms after SDS-PAGE, wherein increasing phosphorylation retards protein mobility. Presumably, it is the most slowly migrating species that represents the heavily phosphorylated and thus highly active form of the kinase (36) . Although four electrophoretic species are readily apparent in serumdeprived cells, the form of slowest mobility represents only a small fraction of the entire p70
S6k pool. In dexamethasone-administered cells, total p70
S6k redistributed into relatively dephosphorylated species, as evidenced by an accumulation of the bulk (85%) of the enzyme into the most rapidly migrating form, designated ␣, whereas immunoreactivity corresponding to the highly phosphorylated enzyme was lost (Fig. 1C) . The close temporal correlation between dephosphorylation of 4E-BP1 and p70
S6k underscores the nature of coordinate regulation of these factors.
Because the proportion of p70 S6k residing in the uppermost band, i.e., the heavily phosphorylated form, represented only a small fraction of the total kinase, the physiological significance of reduced basal activation by glucocorticoids seemed questionable. To address this issue, S6 phosphorylation was determined with the use of an anti-phospho-S6 antibody. Interestingly, the levels of phospho-S6 declined in parallel with the dephosphorylation of p70
S6k observed after addition of glucocorticoids. Within 4 h of drug administration, phosphorylated S6 was reduced to ϳ50% of control values (Fig. 1D) . Thus basal p70
S6k activity maintains S6 in a nominally phosphorylated state that is further diminished by glucocorticoid-induced dephosphorylation/inactivation of the kinase. Although this is a reasonable explanation, the possibility that the decrement in immunoreactive phospho-S6 is caused by another S6 kinase or S6 phosphatase cannot be excluded. Whereas in serum-deprived CTLL-20 cells, 3 h of exposure to dexamethasone reduces p70 S6k activity by 50%, in quiescent NIH3T3 fibroblasts, the drug is completely ineffectual, emphasizing the cell selectivity of p70
S6k regulation by glucocorticoids (22) . Because glucocorticoids are known to modulate the expression of particular genes, it seemed plausible that glucocorticoid-induced dephosphorylation of both p70
S6k and 4E-BP1 could reflect reduced expression of candidate upstream regulators. However, neither the expression of mTOR nor that of PKB/Akt proteins was affected by dexamethasone administration (Fig. 2) . Because in serum-deprived cells phosphorylation of PKB at Ser 473 , which is essential for PKB activation, was undetectable, a comparison of the activation state of PKB in control and dexamethasone-treated cells was Fig. 1 . Glucocorticoids downregulate the phosphorylation states of ribosomal protein S6 kinase (p70 S6k ) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) and facilitate the association of 4E-BP1 with eIF4E. L6 myoblasts were deprived of serum for 24 h and then administered dexamethasone (Dex, 1 M) for the indicated times. Cells were harvested, lysed, and Western blotted with anti-4E-BP1 (A), anti-p70 S6k (C), or anti-phospho-S6 antibodies (D). In the case of p70 S6k , the electrophoretic forms were quantitated and the data expressed as %total p70
S6k in the hyperphosphorylated (HP), i.e., non-␣-, forms. Arrows indicate relative positions of ␣-and HP-forms. Similarly, multiple electrophoretic forms of 4E-BP1 were quantitated and the data expressed as %total 4E-BP1 in the most slowly migrating form, "␥". B: Cell lysates were immunoprecipitated with anti-eIF4E antibody. The immunoprecipitates were then electrophoresed and immunoblotted with anti-eIF4E or anti-4E-BP1 antibodies. The Western blots were quantitated and the data expressed as the ratio of 4E-BP1 to eIF4E in arbitrary units. Data represent Ն3 independent experiments; values are means Ϯ SE. * P Ͻ 0.05, † P Ͻ 0.01 vs. untreated cells by Student's t-test comparison. not possible. However, whereas glucocorticoids acutely attenuate insulin-like growth factor (IGF)-I-stimulated phosphorylation of p70
S6k and 4E-BP1, IGF-I-stimulated phosphorylation of PKB at Ser 473 is refractory to inhibition by glucocorticoids, suggesting that the influence of these hormones is exerted downstream of or parallel to PKB (unpublished results). Furthermore, phosphorylation of eIF4E by the MAP kinase-integrating kinases (Mnks) is believed to enhance the affinity of eIF4E for the 5Ј cap of mRNA and thus to facilitate translation initiation. Neither the expression nor the activation of the Erks and the p38 MAPKs , which activate Mnks and thereby promote eIF4E phosphorylation, were significantly influenced by glucocorticoids (Fig. 2, B-D) .
To determine whether downregulation of eIF4F and p70 S6k was truly caused by specific effects mediated by the glucocorticoid receptor, cells were coadministered substances known to perturb glucocorticoid receptor function. Pretreatment of cells with the heat shock protein 90 (hsp90)-specific compound geldanamycin completely prevented the glucocorticoid-induced effects on 4E-BP1 (Fig. 3A) and corrected dephosphorylation of p70 S6k (Fig. 3B ). This benzoquinone ansamycin antibiotic, via interaction with the hsp90 component of glucocorticoid receptor heterocomplexes, hinders the steroid binding capacity of the receptor, as well as facilitating its degradation (32). Mifepristone Fig. 3 . Glucocorticoid receptor function is requisite for dephosphorylation of 4E-BP1 and p70
S6k in response to glucocorticoids. Serumdeprived L6 myoblasts were incubated in the presence of Dex (1 M) for 4 h or preincubated for 1 h with geldanamycin (1 g/ml) or mifepristone (10 M) before addition of Dex as indicated. A: cell lysates were separated by SDS-PAGE and Western blotted with anti-4E-BP1 antibody. The electrophoretic forms were quantitated and expressed as %4E-BP1-␥, as described in the legend of Fig. 1 . B: cell lysates were separated by SDS-PAGE and immunoblotted with anti-p70 S6k antibody. Multiple electrophoretic forms were quantitated and expressed as %p70
S6k in HP forms as described. Results represent Ն3 independent experiments; values are means Ϯ SE. * P Ͻ 0.05, † P Ͻ 0.01 vs. cells administered Dex alone by t-test comparison. (RU486), a glucocorticoid analog that binds the glucocorticoid receptor with higher affinity than dexamethasone but fails to efficiently transform the receptor, exhibited antiglucocorticoid properties similar to geldanamycin: it entirely abrogated dephosphorylation of 4E-BP1 while returning the phosphorylation state of p70
S6k to that observed in cells administered only mifepristone (Fig. 3, A and B ). An effect of p70
S6k dephosphorylation after exposure to both geldanamycin and mifepristone was noted.
Besides a prerequisite temporal lag, sensitivity to pharmacological translational and transcriptional inhibitors is a defining characteristic of gene induction by steroid hormones. Therefore, emetine, puromycin, and cycloheximide, each of which impairs the translational apparatus, were evaluated for their ability to abrogate dephosphorylation of 4E-BP1 and p70
S6k in response to dexamethasone. Although the inhibitors prevented the glucocorticoid-induced dephosphorylation of 4E-BP1 and p70
S6k , each compound promoted phosphorylation of these factors when administered in the absence of hormone (Fig.   4, A and B, cycloheximide not shown) . Moreover, the same observation was made after treatment with the transcriptional inhibitor actinomycin D (Fig. 5 , B-E and Fig. 6, A and B) . To assess potential nontranslational influences of these inhibitors on p70
S6k and 4E-BP1 phosphorylation, a temporal correlation, or lack thereof, between effector phosphorylation state and protein synthesis inhibition was sought. Indeed, inhibition of protein synthesis by cycloheximide occurred concomitantly with phosphorylation of p70 S6k and 4E-BP1 (Fig. 5, A-E) ; even the more gradual decline in protein synthesis engendered by actinomycin D temporally paralleled the phosphorylation state of these effectors. Modulated phosphorylation of 4E-BP1 and p70
S6k appears to be secondary to translational and not transcriptional inhibition per se, because actinomycin D, which presumably inhibits transcription as a prelude to translational inhibition, did not affect p70
S6k and 4E-BP1 phosphorylation states before inhibition of protein synthesis.
It is noteworthy that dephosphorylation of p70 S6k subsequent to treatment with glucocorticoids correlated with dephosphorylation of Thr 389 , thus supporting the premise that modification of this site accounts for the observed diminution in S6 phosphorylation (Figs. 6D and 1D , and Ser 424 ), which relieves intrasteric occlusion of the kinase's catalytic pocket, is induced after mitogen stimulation (12) . These residues are flanked by a proline in the ϩ1 position, rendering these sites, in vitro, sensitive to phosphorylation by enzymes of the MAP kinase superfamily, as well as other kinases exhibiting prolinedirected substrate specificity. Curiously, phosphorylation of Ser 411 was unchanged after exposure to glucocorticoids. Alternatively, actinomycin D (Fig. 6C ) and okadaic acid (not shown), which promote phosphorylation of the kinase, induced a mild dephosphorylation of this site (Fig. 6C ) concomitant with phosphorylation of Thr 389 (Fig. 6D) . Furthermore, phosphorylation of Ser 411 was refractory to dephosphorylation by rapamycin (Fig. 6C) , whereas neighboring residues Thr 421 and Ser 424 are reportedly much more sensitive to the macrolide (36) . Importantly, dexamethasone does not reduce the phosphorylation status of Thr 389 in cells treated with either actinomycin D (Fig. 6D ) or okadaic acid (not shown) below that observed in cells administered inhibitor alone.
There is an increasing body of circumstantial evidence implicating a protein phosphatase in the mediation of signals propagated by mTOR [(15, 36) and reviewed in (5)]. Therefore, the protein phosphatase-1 and -2A (PP1 and PP2A) inhibitors, okadaic acid and calyculin A, were evaluated for their ability to correct the dephosphorylation of p70
S6k and 4E-BP1 induced by dexamethasone. Indeed, both okadaic acid and calyculin A sufficiently reversed dephosphorylation of p70 S6k (Fig. 7) and 4E-BP1 (not shown) in response to glucocorticoids. In fact, okadaic acid alone potently induced phosphorylation of these effectors (not shown), implying that a PP1 and/or a PP2A-type phosphatase(s) either directly or indirectly regulates the phosphorylation states of p70 S6k and 4E-BP1. Although both okadaic acid and calyculin A completely reversed the glucocorticoid-induced dephosphorylation of p70 S6k and 4E-BP1, this was not due to inhibition of newly induced conventional phosphatases, because the relative expression levels of PP1 and PP2A c , the catalytic subunit of PP2A, was not appreciably altered by glucocorticoids (not shown).
DISCUSSION

The translational effectors p70
S6k and eIF4E comprise a translational unit distinguished by its sensitivity to both the fungal metabolite wortmannin and the immunosuppressive antibiotic rapamycin, which inhibit the phosphotransferase activities of PI-3 kinase and mTOR, respectively. The synthesis of D3-phosphorylated phosphoinositides at the plasma membrane by PI-3 kinase recruits pleckstrin homology domaincontaining proteins such as the phosphoinositide-dependent kinase 1 (PDK1) and PKB. It is believed that this colocalization at the membrane promotes efficient phosphorylation of PKB by PDK1, whose activity appears to be constitutive. PDK1 also phosphorylates p70
S6k at a site that is analagous to that phosphorylated on PKB (1, 26) and that is indispensable for S6 kinase activity (24) . Although initial studies utilizing a membrane-localized form of PKB implied that this kinase was upstream of p70 S6k , recent evidence suggests that such PKB-mediated activation of p70
S6k is artifactual and in fact derives from constitutive membrane association rather than from bona fide substrate selectivity (8) . The phosphorylation status of 4E-BP1, however, does appear to lie downstream of PKB, because a dominant-interfering PKB variant prevents the phosphorylation of 4E-BP1 but not p70
S6k (8) . Moreover, PKB phosphorylates mTOR on Ser 2448 , a site phosphorylated in response to insulin (23) . Therefore, because both PKB and mTOR kinase activities are enhanced in response to insulin, and because mTOR-mediated 4E-BP1 phosphorylation is enhanced upon selective activation of a PKB/estrogen receptor chimera (31), a signal propagated via a PI-3 kinase/ PKB/mTOR pathway is likely to regulate 4E-BP1 and thus eIF4E. However, it should be emphasized that accumulating evidence suggests that direct regulation of 4E-BP1 by mTOR is insufficient to explain 4E-BP1 phosphorylation observed in vivo (11, 13) . At least in vitro, mTOR can phosphorylate p70
S6k on both Thr 389 and on the carboxy-terminal cluster of proline-directed sites and does so cooperatively with PDK1 (14) . Evidence has also emerged that mTOR may regulate PP2A and thereby exert an indirect effect on the phosphorylation status of p70 S6k (25) . Although TOR control of PP2A is better understood in yeast (15) , evidence for a similar mechanism in mammalian cells remains largely circumstantial.
Despite the obvious complexity of regulation of p70
S6k and 4E-BP1, the data reported herein support reasonable conclusions regarding the modulation of this translational component by glucocorticoids. If glucocorticoids are transcriptionally affecting distal PI-3 kinase effectors, then the event(s) that determines their respective phosphorylation states is caused by induction or repression or both. At present, the nature of such transcriptional phenomena is uncertain. It is clear, however, that abrogation of the influences of glucocorticoids by actinomycin D, cycloheximide, emetine, and puromycin is related to translational inhibition. Although the transcriptional inhibitor actinomycin D augments both p70
S6k and 4E-BP1 phosphorylation, it does not do so until protein synthesis is attenuated (Fig. 5) , suggesting that the resultant p70
S6k and 4E-BP1 phosphorylation states are not due to artifactual activation of upstream signal transduction pathways; rather, a signal emitted by the crippled translational machinery may negatively, but futilely, feed back to p70
S6k and 4E-BP1. Indeed, the notion of translational regulation by feedback mechanisms has been suggested. For instance, overexpression of eIF4E in a tetracycline-inducible background reduces p70
S6k and 4E-BP1 phosphorylation in proportion to the degree of eIF4E expression (17) . Because the activation state of PKB, an upstream regulator of mTOR, was unaffected by eIF4E induction, it was proposed that a sensor for translational homeostasis lies downstream of PKB. Nevertheless, correction of glucocorticoid-induced dephosphorylation of p70
S6k and 4E-BP1 by transcriptional and translational inhibitors appears to be contingent on protein synthetic inhibition.
Because dexamethasone treatment results in accumulation of p70
S6k -␣, it is reasonable to speculate that this may be caused by inhibition of the initial series of phosphorylation events occurring within the carboxy terminus of the kinase. All of these phosphorylation sites are situated in Ser/Thr, Pro motifs and, as such, are readily phosphorylated by MAP kinase and cyclindependent kinase family members in vitro. Whereas mTOR can also phosphorylate these residues in vitro (14) , it is unlikely to be the physiologically relevant serum-activated kinase, because in an amino-terminal truncation background, phosphorylation of these clustered sites in response to serum is unabated by rapa- Fig. 1 389 , which lies within a hydrophobic segment interjacent to the catalytic loop and the carboxy terminus, cooperatively evokes full activation of the kinase (7, 36) . Moreover, deletion of the amino and carboxy termini, which renders the kinase resistant to inhibition by rapamycin, also reveals that phosphorylation of Thr 229 persists in the basal state, whereas phosphorylation of Thr 389 occurs only after mitogen stimulation (6) . The Thr 229 kinase has been identified as PDK1 (26) , whose constitutive activation may explain perpetual phosphorylation of this site when the steric constraints of the amino and carboxy termini are alleviated by truncation. It is also noteworthy that phosphorylation of either Thr 229 or Thr 389 alone is associated with only 2-5% p70 S6k activity, whereas phosphorylation at both sites synergistically evokes complete activation. Under conditions of serum depletion, the hyperphosphorylated form of p70 S6k remains mildly discernible (Fig.  6B) , as does basal phosphorylation of Thr 389 (Fig. 6D) ; glucocorticoids render the corresponding signals undetectable. Furthermore, dexamethasone-induced dephosphorylation of Thr 389 correlates with dephosphorylation of the endogenous p70
S6k substrate, ribosomal protein S6. Targeted deletion of p70 S6k in murine embryonic stem cells completely abolishes S6 phosphorylation, suggesting that p70
S6k is largely responsible for S6 phosphorylation in vivo (16) . Therefore, dephosphorylation of S6 in response to glucocorticoids is likely to be mediated by dephosphorylation of p70
S6k at Thr 389 . The mechanism of dexamethasone-induced dephosphorylation of 4E-BP1 remains cryptic. It is clear, however, that the observed dephosphorylation is sufficient to promote sequestration of eIF4E by 4E-BP1 (Fig. 1B) . The kinase activity associated with or intrinsic to mTOR phosphorylates 4E-BP1 in vitro and in transiently transfected HEK293 cells (2) . Moreover, Thr 37 and Thr 46 are specifically targeted by mTOR, albeit the functional consequence of phosphorylation at these sites remains contentious (3, 11) . Nonetheless, mTOR is a likely candidate for regulation of 4E-BP1 phosphorylation by glucocorticoids; if regulation of mTOR kinase activity does indeed occur, it is not via downregulation of the mTOR gene ( Fig. 2A) .
Glucocorticoids induce a clear redistribution of 4E-BP1 into ␣-and ␤-electrophoretic forms (Fig. 1A) , both of which retain the capacity to associate with eIF4E (Fig. 1B) ) requires previous phosphorylation of Thr 37 and Thr
46
, the latter sites are proposed to prime 4E-BP1 for subsequent phosphorylation (11) . It has been demonstrated that all three electrophoretic species of 4E-BP1 are detectable with the use of antiphosphopeptide antibodies specific for Thr 37 and Thr 46 , although the antibodies cannot discriminate between either site (11) . Because 4E-BP1 exists predominantly in ␣-and ␤-forms after glucocorticoid administration, and because both ␣-and ␤-forms are phosphorylated at Thr 37 and/or Thr 46 , it seems plausible that glucocorticoids may attenuate the same serum-activated effectors that regulate the carboxy-terminal, serum-sensitive phosphorylation sites.
The distal element of the PI-3 kinase signal transduction cassette, comprised of mTOR, 4E-BP1, and p70
S6k
, is recognized as a critical site of translational control in mammalian cells and, as such, has been the focus of widespread investigation. Herein, we report that glucocorticoids negatively regulate eIF4E and p70
S6k function in undifferentiated rat L6 skeletal myoblasts in a manner that appears characteristic of classical steroid hormone action in that the process requires several hours to emerge and is sensitive to transcriptional and translational inhibition. Furthermore, the close temporal correlation between modulation of 4E-BP1 and p70
S6k suggests that this mutual regulation may involve a common mechanism. Dephosphorylation of ribosomal protein S6 is secondary to dephosphorylation of p70 S6k at Thr
389
, but not at Ser 411 , suggesting that glucocorticoids deactivate p70
S6k through site-selective dephosphorylation.
